retatrutide phase 2 results 2024 2025 The numbers from Lilly's 3 trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user Percent of participants achieving liver

Tirzepatide is the first combination of entero-pancreatic hormones [dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) RA] that has been approved for T2D management based on the findings from the phase 3 SURPASS programme

These physical indicators, combined with internal health markers, provide a more complete picture of your progress

doi: 10.1080/00365521.1997.11720715 13 GillSRPopMDeboyRTEckburgPBTurnbaughPJSamuelBSet al

From a management perspective, with the necessity of glucose-lowering medications like metformin or basal insulin in populations with T2DM complications, 61 combination products with routine injections or basal insulin may offer compliance advantages, simpler titration strategies (adjusting to maximum maintenance dose only once), and lighter economic burdens